Takeda Pharmaceutical Company Limited
TAK
$15.46
$0.362.38%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -533.93% | -74.81% | 1.34% | 3,105.63% | -102.84% |
| Total Depreciation and Amortization | -20.06% | -5.32% | 4.99% | 18.75% | -18.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.58% | 293.17% | -161.22% | 95.42% | 79.19% |
| Change in Net Operating Assets | -96.76% | 121.95% | 121.51% | -404.71% | 135.56% |
| Cash from Operations | -42.07% | 33.12% | 73.01% | -41.78% | 89.15% |
| Capital Expenditure | -8.29% | 11.18% | 9.68% | -22.83% | 5.94% |
| Sale of Property, Plant, and Equipment | 300.00% | -73.09% | 238.13% | 327.41% | -99.25% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 5,352.78% | -77.21% | 92.16% | -85.71% | -- |
| Other Investing Activities | 46.19% | -124.98% | 68.11% | -166.34% | -27.70% |
| Cash from Investing | 82.96% | -49.90% | 49.72% | -142.71% | 18.78% |
| Total Debt Issued | -31.28% | -91.61% | -6.07% | 17,021.27% | -101.76% |
| Total Debt Repaid | 54.79% | 6.50% | -600.25% | -591.96% | 88.32% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 93.30% | -1,441.03% | 93.02% | -1,341.26% | 93.44% |
| Other Financing Activities | 2.69% | -26.65% | -216.96% | 176.85% | -5.51% |
| Cash from Financing | 53.96% | -480.96% | -136.48% | 617.51% | 40.78% |
| Foreign Exchange rate Adjustments | -142.43% | 153.37% | -354.46% | 55.30% | 437.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.10% | -758.53% | -83.69% | 95.15% | 667.42% |